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Abstract 
Background: Inflammatory bowel disease (IBD) is known to reduce expression of the gene caudal 
type homeobox transcription factor 2 (CDX2). CDX2 has a critical role in differentiation of intesti-
nal epithelial cells (IEC), as well as in regulating several intestinal specific genes, including meprin 
1A (MEP1A). Recent studies have indicated the existence of a previously unidentified isoform of 
CDX2, expressed from an alternative, CUG start codon, termed variant-CDX2 (vCDX2). Further-
more vCDX2 mRNA has been shown to be highly expressed in IECs of IBD patients.  
Aim: This study investigates whether vCDX2 give rise to a protein and the nature vCDX2 as a tran-
scriptional factor, in relation to CDX2’s effect on the MEP1A-promotor. 
Methods: Translation of vCDX2 was enhanced by changing the start codon from CUG to AUG 
using site directed mutagenesis. A western blot was used to determine the translation of vCDX2. A 
dual luminescence reporter gene assay was used to quantify the effect of vCDX2 and CDX2 on the 
activity of the MEP1A-promoter.  
Results: The western blot confirmed that vCDX2 is translated into a protein. The reporter assay 
showed that the effect of CDX2 on the expression of MEP1A was significantly reduced when 
vCDX2 was present.  
Conclusions: vCDX2 is translated into a protein. vCDX2 has a dominant negative effect on CDX2 
as a transcriptional factor on the MEP1A-promotor.  
 
Resumé 
Baggrund: Inflammatorisk tarm sygdom (IBD) vides at reducere ekspressionen af genet caudal 
type homeobox transcription factor 2 (CDX2). CDX2 spiller en vigtig rolle i differentieringen af 
tarm epitheliale celler (IEC) og i reguleringen af flere intetinal specifikke gener, her i blandt meprin 
1A (MEP1A). Nylige studier har indikeret eksistensen af en hidtil ukendt isoform af CDX2 udtrykt 
fra et alternativ CUG start codon, navngivet variant CDX2 (vCDX2). Endvidere er vCDX2 mRNA 
højt udtrykt IEC’erne hos patienter med IBD.  
Mål: Dette studie undersøger hvorvidt vCDX2 giver ophav til et protein og hvilken måde vCDX2 
som en transskriptions faktor i relation til CDX2’s effekt på MEP1A-promotoren. 
Metode: Translationen af vCDX2 var forstærket ved at ændre start codonet fra CUG til AUG ved 
hjælp af site directed mutagenesis. Et western blot bestemte translationen af vCDX2. En dobbelt 
luminans rapporter gen assay blev brugt til at kvantificere effekten af vCDX2 og CDX2 på udtryk-
ket af MEP1A-promotoren.  
Resultater: Western blottet fastslog at vCDX2 bliver translateret til et protein. Rapporter assayen 
viste at effekten af CDX2 på udtrykket af MEP1A var signifikant reduceret når vCDX2 var til stede.  
Konklusion: vCDX2 bliver translateret til et protein. vCDX2 har en dominant negativ effekt på 
CDX2 som en transskriptions faktor på MEP1A-promotoren.  
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Nomenclature  
This section will by explicit formulations define all abbreviation of words.  
Genes and mRNA in human cells are written with capital letters and in italic, examples: vCDX2. 
Proteins from human cells are written in capital letters and in normal font, examples: vCDX2. 
Genes and mRNA in rat or mouse cells are written, first letter in capital and all the letters in italic, 
examples: vCdx2. Proteins from rat or mouse cells are written capital first letter and not in italic, 
examples: vCdx2. 
Restriction enzymes are written in italic, examples, EcoI, XbaI. 
All latin names are in italic, example, intestinum tenue. 
Abbreviations will be written out the first time they occur and will have its abbreviations mentioned 
in parentheses after its full written name. examples, caudal type homeo box transcription factor 
2(CDX2).  
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Introduction 
Inflammatory bowel disease (IBD) is defined as conditions of chronic or relapsing immune activa-
tion and inflammation within the gastrointestinal tract and is of concern in the western world(1). 
The epidemiological data of IBD show a mean of annual incidence of 8.6/100,000 for Crohn´s dis-
ease (CD) and a mean of annual incidence of 13.4/100,000 for ulcerative colitis (UC), in the popu-
lation of the Danish city and county of Copenhagen(2). The symptoms of IBD include but are not 
limited to, abdominal pain, fever, and clinical signs of diarrhea with passage of visible blood and/or 
mucus. Additionally the risk of colorectal cancer has been estimated to a incidence ratio as high as 
26.6(3). Although IBD is known to have a polygenetic basis, the concordance rate for CD in 
monozygotic twins has been estimated to lie within 20% to 50% in Scandinavian studies(4). The 
consensus hypothesis is that the etiology of IBD consists of multiple factors of both endogenous 
and exogenous origin (5). One endogenous aspect of IBD is the transcription factor caudal type 
homeobox transcription factor 2(CDX2), which has been shown to be under expressed in patients 
with active and inactive IBD (6;7). Cdx2 regulate morphology and cell differentiation of intestinal 
epithelial cells (IECs) (8). Recent studies by Prof. Sandelin A. as referred in (9) by Dahlgaard, K. 
have indicated the existence of, a naturally occurring, previously unidentified, isoform of CDX2, 
termed variant-CDX2 (vCDX2), which seems to be up-regulated in patients with IBD. In order to 
gain a better understanding of vCDX2, further experiments are needed and will be the focus of this 
study. 
Study hypothesis  
One aspect of vCDX2 could be that it is in competition with CDX2 for the binding of CDX2 regu-
lated promoters. The intestinal specific meprin-α gene, MEP1A, is down-regulated in patients with 
IBD (10). A direct result of CDX2 Knock down in Caco-2 cells has been a MEP1A expression re-
duction of 40% (7). To investigate possible vCDX2 interactions we focus on the promoter of the 
MEP1A. Further, the availability of reporter constructs containing a MEP1A–promoter, at The De-
partment of Science, Systems and Models at Roskilde University, generously provided by Prof. 
Troelsen J. has led our team to focus on the effect of CDX2 and vCDX2 on the MEP1A-promoter 
activity for quantitative analysis, in order to determine whether vCDX2 is a dominant negative of 
CDX2´s effect of MEP1A-promoter. 
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Problem proposal 
Does vCDX2 give rise to a protein and what is the function of vCDX2 as a transcriptional factor, in 
relation to the effect of CDX2 on the MEP1A-promotor? 
Study Boundaries  
This study is an experimental study, focusing on vCDX2 and its effect of CDX2 on the MEP1A-
promoter. Results from the experiments will be put into context of IBD. This study will consult lit-
erature about IBD and cancer in relation to CDX2 function as a homeodomain transcription factor 
and furthermore will not include any litterateur on other CDX-family homeoproteins. This study 
will not focus on secondary diseases caused by IBD such as colorectal cancer, rheumatoid arthritis, 
erythema nodosum, hepatobiliary diseases, ect. 
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Theory  
The anatomy of the intestinal tract and its relation to IBD 
IBDs are a group of gastrointestinal diseases, the two major of which are CD and UC. Therefore 
this section introduces the anatomy of the healthy intestinal tract and gives a short description of 
both CD and UC.  
The intestinal tract, which is a part of the abdominal cavity, consist of 2 major parts; intestinum 
tenue and intestinum crissum. Intestinum tenue is responsible for digestion and absorption of nutri-
ents and contain a highly developed villié. Intestinum tenue and intestinum crassum are intercon-
nected through caecum. Intestinum crassum consists of the ascending, transverse, descending and 
sigmoid colon and ends up in the rectum. 
The intestinal tract from esophagus to rectum consists of four different layers called canalis alimen-
tarius. The first layer is the tunica mucosa. The apical end toward the lumen is called lamina epi-
thelialis mucosa. Lamina propia mucosa consist of connective tissue and is highly vascularized, 
innervated and contains Peyer's patches which are an immune nodulus. Lamina muscularis mucosa 
is a small layer of smooth muscle tissue before tunica submucosa which is a thick layer of connec-
tive tissue. Tunica muscularis consists of two major muscle layers that lie circularly and longitudi-
nally, and is responsible for the peristaltic movement of the intestines. Tunica serosa is the last lay-
er that interconnects with the mesenteric peritoneum(11) see figure 1.  
CD is a disease that can affect the whole intestinal tract. It includes a transmural segmental inflam-
mation and most often include proximal caeum region. UC is a mucosal inflammatory response that 
includes the mucosa and superficial tunica submucosa where ulcerations can be observed. Rectum 
and the distal colon is often the place of inflammation, though the entire length of colon can be af-
fected and thereby be classified as pancolitis. In both diseases the affected areas are often infiltrated 
with mononuclear and polymorph nucleated cells, causing inflammation (12).  
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Figure 1 Cross section of 
canalis alimentarius: 
The figure demonstrates a cross 
section of the 4 layers in canalis 
alimentarius. V, Villi. Muc, 
Mucosae. MM, Muscularis 
Mucosae. SubM, Submucosae. 
ME, Tunica Muscularis. C, 
Circular layer of Tunica Muscu-
laris. L, Longitudinal layer of 
Tunica Muscularis, S, serosae. 
Figure from (11), page 617. 
 
 
Lieberkühns Crypts 
The inflammation caused by IBD interferes with the intestinal homeostasis and affect the differenti-
ation of IECs. Therefore this section will introduce the lieberkühns crypts where the IECs differen-
tiation takes place.  
The lieberkühns crypts are glands found in the epithelium. The crypts contains six different kind of 
cells: Stem cells, paneth cells, entrocyte cells, golbet cells, enteroendokrine cells and transit 
amplifying (TA) cells. The stem cells and paneth cells are concentrated in the valley of the crypt. 
Above them the TA cells line the walls of the crypts. At the apical surface of the crypt the goblet, 
entroyte and enteroendorkrine cells resides(13). The paneth cells form part of the innate immune 
defense due to their ability to secreate antibacterial molecules(14). The TA cells have the capability 
to differentiate into paneth cells, where they move down into the crypt valley, or differentiate into 
goblet, enterocytter or enteroendokrine cells where they move upwards to the apical surface of the 
crypts.  
Goblet cells function is to secrete mucin, which dissolves in water to become the mucus layer, 
which forms a primary barrier against pathogenic infections (15) and lubricates the lumen of the 
intestine. One of the genes responsible for mucin production is MUC-2. MUC-2 has been shown to 
be a CDX2-target gene(15;16). Studies of IBD conducted on human tissues have shown that 
malfunctions of the intestinal innate immune defense, changes in the expression of mucins and 
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structual reconfiguration of the claudins, a tight junction protein, in the intestine are firmly related 
to IBD(17-19).  
 
Meprins 
Meprins exist as two genes, MEP1A and MEP1B. Meprins are zinc metalloendopeptidase located 
and expressed at the apical membrane of IEC (20). Meprins are highly expressed in the intestine, 
either as membrane bound or secreted into the luminal content (21;22). Meprins consist of two sub-
units forming dimers(20). Merpin A and B have distinct properties in regard to substrate specificity; 
the β-subunit has specificity for negatively charged amino acids residues, while the α-subunit has 
specificity for hydrophobic residues (23). As MEP1A has been associated with IBD, it will be the 
focus of this study. Knockout mice lacking MEP1A are more susceptible to Dextran-Sodium-
Sulfate (DSS) induced colitis, which mimic UC symptoms, than wildtype mice (10). Likewise, the 
MEP1A has been reported to be down-regulated in mice with DSS induced colitis (23). Recently a 
MEP1A-polymorphism (rs1059276) has been associated with UC by a case control study in humans 
(10). Furthermore MEP1A mRNA is found to be decreased in the colon of IBD patients compared 
to healthy controls (10). These data held together clearly indicate an association between MEP1A 
and IBD. Therefore MEP1A is a candidate for a model gene studying the effect of vCDX2 on the 
CDX2 transcriptional regulation in regard to IBD.  
 
Intestinal homeostasis and CDX2 
As said in the introduction the etiology of IBD is currently unknown (12), however a consensus 
hypothesis is that the cause of IBD includes polygenic traits, exogenous factors and endogenous 
factors (12). The mucosal immunology is currently considered to have a key role in the pathogene-
sis of IBD (24). Current treatment for both UC and CD leans towards anti-inflammatory regimen 
such as methotrexat or use of biological-based pharmaceuticals such as antibodies against key cyto-
kines in the pathogenesis, like Tumor Necrosis Factor alfa (TNF-α)(12;25). In IBD the persistent 
and prominent immunological reaction to the luminal content is affecting the intestinal barrier func-
tion and homeostasis which causes the symptoms associated with IBD (6-8;26;27). 
A candidate gene in relation to IBD, among others that affects the intestinal homeostasis, is CDX2 
(6). The CDX2 is a transcription factor that has been shown to have an important role in maintain-
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ing the intestinal homeostasis and integrity in several studies (6;15;26;27).The CDX2 has been 
reported to be specifically expressed along the intestinal tract (28). Furthermore CDX2 expression 
does have an autoregulatory potential on its own transcription (7;29).  
Several studies have elucidated a pivotal role of CDX2 in intestinal homeostasis, differentiation and 
regulation of intestinal specific genes at the transcriptional level (6-8;26;27), also colorectal cancer 
differential state has been shown to be dependent on the CDX2 expression (30). To address the im-
portance of regulation of Cdx2, several studies has shown that Cdx2
 -/-
 knockout mice doesn’t sur-
vive to term (26). Cdx2 
+/-
 mice does survive, are fertile but express metaplastic gastric like epithe-
lium following the loss of Cdx2-expression (26). 
Genes like MUC-2 and MEP1A are not the only genes in association with IBD (6;10;15;23), but are 
also regulated by CDX2 at the transcriptional level (6). Mucus produced by goblet cells in the 
lieberkühns crypt via the MUC-2 gene is an innate part of the immunological defense against path-
ogens (15) and studies suggest a CDX2 transcriptional regulation (6;27). TNF-α has been shown to 
inhibit the Cdx2 expression in DSS induced colitis, in mice (6). The down regulation of CDX2 was 
first proposed by Kim, S.et al(31) who suggested that TNF-α signaling through nuclear factor κβ 
(NFκβ) dimers p50/50 and p65/p50 had direct interaction with the CDX2-promoter. Therefore it is 
plausible and reasonable to suggest that an altered mRNA level of CDX2 in the IEC has a promi-
nent role in the balance between intestinal homeostasis, inflammation and MEP1A expression.  
 
vCDX2 
The inhibition of CDX2 translation is, as described in a previous section, a factor in the pathogene-
sis of IBD. Recent studies by Prof. Sandelin A. as referred in (9) by Dahlgaard, K. determined the 
expression of an unknown isoform of CDX2, in patients with IBD. Cap Analysis of Gene Expres-
sion (CAGE) determined the mRNA of vCDX2 originated from an alternative promoter(9). This 
isoform is speculated to be expressed from an alternative mRNA transcript with a CUG codon in 
frame with exon-2 and exon-3. Utilization of a CUG codon in frame with exon-2 and exon-3 and 
containing an alternative exon-1 of 92 nucleotides, CDX2( refseq: NM_001265.4). 
The normal CDX2 exon-1 contains the sequence coding for a caudal like protein activation domain, 
and it is found in the 13-180 amino acid region of the CDX2 protein. The vCDX2 retains the amino 
acid coding for the DNA binding homeodomain. The vCDX2 protein is therefore likely to bind to 
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its corresponding regulatory sequence via the binding homeodomain. Due to an absent protein acti-
vation domain, vCDX2 should be unable to provide any protein-protein interaction with the tran-
scription complex. CDX2 and vCDX2 therefore compete for the same regulatory sequences, how-
ever only CDX2 can activate the transcription complex. The competition between CDX2 and 
vCDX2, might be dominant negative in regards to the regulatory functions. The proposed inhibition 
of the CDX2 function by vCDX2 might mimic the effect of the down regulation induced by TNF-α 
(6).  
All though the mechanism behind non-AUG translation are not fully understood, it is known that 
the nucleotide sequence around the start codon as well as the secondary structure of the mRNA af-
fects the ribosomal initiation complex (32). It has also been shown that splice variance, cellular 
stress and several trans-acting factors can increase the initiation from non-AUG codons(33;34). 
It’s important to note that isoforms from an alternative non-AUG translations are expected to con-
tain a methionine at the N-terminal even if the start codon doesn’t code for methionine, see the 
scanning model section below.  
It’s important to note that isoforms from an alternative non-AUG translations are expected to con-
tain a methionine at the N-terminal even if the start codon doesn’t code for methionine, see the 
scanning model section below. Proteins that are initiated from non-AUG start codons which are in 
frame with a primary transcript will differ from native protein, due the change in the number of 
amino acids. The change can affect key features such as function and regulation, or may have no 
apparent influence. Data indicate however that non-AUG coded proteins can represent an important 
regulatory mechanism induced by intracellular events, such as, the gene human fibroblast growth 
factor 2, that is synthesized from CUG codon when the cells are exposed to heat shock or oxidative 
stress(35).  
 
Scanning model 
In normal ribosomal translation of mRNA, the small ribosomal subunit (40S) binds to the 5’cap 
together with eukaryotic initiation factor 3 (eIF3) and a eukaryotic initiation factor 2 (eIF2) charged 
with tRNA methionine. eIF3 and eIF2 primes the elongation complex which then scans the mRNA 
from its 5’ cap until it encounters an AUG codon, preferably in a good Kozak sequence and initiates 
translation.  
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A Kozak sequence is a number of conserved nucleotides surrounding the initial start codon in eu-
karyotes. The Kozak sequence is necessary to halt the initiation complex and allow the ribosomal 
subunit 80S bind to the complex and elongation initiates, this known as the scanning model. The 
consensus Kozak sequence was first described in 1987, when Kozak M. analyzed the mRNA of 699 
vertebrates(36). 
The scanning can halt on an inferior Kozak sequnce or bypass the primary start codon through sec-
ondary structures or leaky scanning. In the case of a non-AUG start codon the nucleotides surround-
ing might require a conserved Kozak sequence. Also one of the nucleotides of a start codon can 
differ from AUG and still bind a methioninen-tRNA through the wobble effect. An inferior Kozak 
sequence upstream from the primary AUG codon can therefore be used, in a small percentage of all 
initiations(34). 
The likelihood of non-AUG initiation increases when a stable hairpin structure is located down-
stream from the non-AUG start codon, as it can halt the initiation complex increasing the likelihood 
of successful alternative initiation(32). In rare incidences the initiation complex can simply fail to 
initiate at the primary start codon and initiation may occur downstream. However this is almost 
never seen if the primary codon is an AUG is in the conserved (strong) Kozak sequence.  
Another bypass mechanism is initiation at an out of frame inferior Kozak sequence upstream from 
the primary codon. The elongation will move the ribosome, bypassing the primary start codon. The 
out of frame initiation will often encounter a stop codon shortly after initiation and terminate elon-
gation, without disassociate from the mRNA. Scanning can then resume and will initiate from a 
new downstream Kozak sequence. The binding of certain cellular proteins at the 5’ and 3’ end can 
also inhibit the translation from the primary start codon by influence the initiation complex’s ability 
to recognize start codons and their Kozak sequence as referred in the review by Touriol C (37).  
While a non-AUG codon can be used to translate certain isoform proteins. They are almost never 
equal to the primary mRNA transcript, from an AUG start codon. Proteins which are primarily ini-
tiated from non-AUG codons exist, but they are very rare in eukaryotes(38).  
A study by Starck RS et al.(33) On a single bistronic trans-gene showed that compound NSC119893 
is a specific inhibitor of methionine-tRNA, associated with eukaryotic initiation factor two (eIF2). 
This will inhibit AUG initiated translation, but only have a minor effect on CUG initiation. Further 
screening of other transcription initiation inhibitors, such as suramin and aurin tricarboxylic acid 
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showed inhibition of AUG translation and enhancement of CUG translation. A fourth inhibitor acri-
flavine inhibited CUG initiation more than AUG initiation (33). The proteins from the inhibited 
cells showed N-terminals with both leucine and methionine in contrastto the accepted model, which 
indicates that the eIF2 is primed with methionine only, this indicates that CUG start codons can be 
initiated from an methionine-tRNA independent pathway (33).  
 
vCDX2 possible influence on IBD 
CD and UC are, as described above, affecting different histological structures, in the intestinal wall 
(12). In UC, the inflammation is located to tunica mucosae where ulcerations and erosive lesions 
can be observed; likewise immune cells in lamina propia can be detected. CD is transmural and 
immune cells can infiltrate each layer of the intestinal wall (12). Macrophages and neutrophils pro-
duce high amounts of reactive oxygen species (ROS). ROS is increased in colonic tissue from IBD 
patients when compared to a control, Keshavarzian et al. as referred in the review by Roessner A. 
(39). The ROS production is caused by an increased inflammatory state of the colon. Furthermore 
TNF-α is known to decrease the Cdx2 level in the cell see figure 2 (6;31).  
ROS and TNF-α are both know to cause cellular stress, and activate the unfolded protein response 
(UPR), which phosphorylates the eukaryotic initiation factor 2 (elF2) to elF2-p as referred in (40) 
by Kaser, A et al. Phosphorylation of elF2, renders the initiation factor unable to bind to 40S there-
by suppressing general translation of AUG codons, including CDX2 (33). The CAGE analysis con-
ducted by Prof. Sandelin A. as referred in (9) by Dahlgaard, K. showed that tissue from colonosco-
py of IBD un-inflamed and IBD inflamed patients, decreased the expression of CDX2 while in-
creasing vCDX2 mRNA. We suggest that vCDX2 is translated from a CUG start codon in frame 
with exon-2 and exon-3 of the CDX2. Likewise we propose that vCDX2 have a dominant negative 
effect on the role of CDX2 in intestinal homeostasis. By suppressing CDX2 translation, the auto 
regulatory potential suppresses the differentiation of IEC, see figure 2.  
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Figure 2 The proposed mechanism of CDX2 and vCDX2 effect on that maturation of IECs:  
The green line with an arrow indicates a positive effect and the flat red line indicates a negative effect. 
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Overview of methods 
The laboratory work consists of several steps in order to determine the in vitro effect of vCDX2 
expression on the MEP1A-promoter. The first step will be cloning of a plasmid, containing the 
vCDX2 gene and a 3x-FLAG sequence, with an AUG start codon, in a good Kozak sequence, to 
ensure an increased vCDX2 expression, of the transfected cells. The cloned plasmid needs to be 
amplified in a bacterial host. The plasmid will be transfected into a humane cell line and the pres-
ence of the gene product will be determined by a western blot with FLAG specific antibodies. The 
plasmids will have their 3x-FLAG removed and the plasmids reinserted into human cells. The 
CDX2 and vCDX2 transcriptions factor function on the MEP1A-promoter will be measured through 
a promoter coupled luciferase gene. See appendix I for flowchart overview of laboratory work, and 
protocols.  
 
Reflection of methods 
It’s unknown if the vCDX2 is expressed from the CUG codon, and if the cell cultures will express a 
CUG codon as expected. To ensure this, an AUG codon in a good Kozak sequence will replace the 
CUG codon in the vCDX2 vector by site directed mutagenesis. Both vCDX2 vectors (AUG and 
CUG) contain a 3x-FLAG for visualization on a western blot, and will be transfected to a suitable 
IEC model. The cells will be lysed and the total protein measured prior to the western blot so an 
equal amount of total protein is analyzed. The data from the western blot will show the relative 
amount of vCDX2(AUG) vs. vCDX2(CUG), when coupled to an internal standard. The size of the 
visualized protein can be compared with a protein marker. The expected size of vCDX2 is 20.8 kDa 
if initiated from the CUG codon. 
The vCDX2 and CDX2 competition on the MEP1A-promoter will be measured by the expression of 
a coupled luciferase gene. The 3x-FLAG tag used in the western blot might interfere with the ter-
tiary structure of the protein and will be removed prior to any protein function analysis.  
 
Statistical reflection 
Statistical analysis will be performed by Wilcoxon-Mann-Whitney U-test method. Data will be pre-
sented as mean of samples, and standard error. A        is considered significant, lowest samples 
size needed is four. 
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Materials and Methods 
Cloning strategy for vector mutation  
The original template pcDNA3.1vCDX2-3xFLAG was amplified by a Polymerase Chain Reaction 
(PCR), utilizing Infusion cloning kit from Clontech laboratories inc.(Mountain View, California, 
USA), with the following primers, their relation to vCDX2 can be seen in figure 3.  
Forward primer: 5’-CATCGCACCATGGGTCACTGTGCACATGCTAGG-3’  
Reverse primer: 5’- GACCCATGGTGCGATGCCCAGGAATTCCACCAC-3’ 
  
  
Figure 3 Primers in relation to vCDX2 gene: 
The forward and reverse primers used for site directed mutagenesis and their placement in relation to the vCDX2 gene 
in pcDNA3.1vCDX2-3xFLAG. The green bar represents the 5’ of the original vCDX2 mRNA. 
 
The PCR was performed with Phusion Hot Start II High-Fidelity DNA Polymerase, Phusion GC 
buffer and DMSO from Thermo scientific (Vilnius, Lithuania) and dNTP’s (50mM in house stocks 
solution, Roskilde, Denmark). The PCR was performed in four reaction setups, differing in the pri-
mary annealing temperature 60-63 °C and 60-62 °C was duplicated with 3 % DMSO, see table 1, 
and performed with the cycle setup seen in table 2 
 
Table 1 the concentration of the PCR components Table 2 The PCR cycle setup 
 
Components Final concentraion 
H2O variable 
5x Phusion GC Buffer 1 
50mM dNTP´s 200µM of each nucleotide 
Reverse primer 0.5µM 
Forward primer 0.5µM 
Template DNA 0.2ng/µL 
DMSO 3% 
Phusion Hot start II DNA polymerase 0.05U/µL 
 
Cycles Time (s) Temperature (°C) 
1 30 98 
7 30 98 
15 60,61,62,63 
210 72 
30 
 
30 98 
210 72 
1 420 72 
1 ∞ 4 
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The PCR product with the 63°C annealing temperature, was extracted from the gel with the 
E.Z.N.A. gel extraction kit spin- protocol from Omega biotek (Atlanta, Georgia, USA). The extract-
ed PCR fragment was recombined to a circular unit with 1X In-Fusion HD Enzyme Premix from 
Clontech laboratories inc. (Mountain View, California, USA) see figure 4. 
The circularized plasmid was then amplified in Mach1™ competent E. coli cells. Ampicillin re-
sistance was used to screen for transfection, pUC19 was used as a positive transfection control. 10 
colonies were selected for plasmid extraction with Nucleo Bond ® Xtra Midi/Maxi kit from Ma-
cherey-Nagel (Düren, Germany). 
 
 
Figure 4 infusion cloning procedure: A) Yellow area representing the 15bp site where pcDNA3.1vCDX2-
3xFLAG is modified. B) Annealing of the primers with 5´containing the mutation and 3´end annealed to the template 
DNA. C) Amplification with DNA polymerase extended in a PCR machine to a linear double-stranded DNA string 
containing the mutated area in both ends. D) The 15bp mutated area aligns and the homologue area and recombines. E) 
New circular plasmid containing the mutation. (Figure from Mutagenesis with In-Fusion® HD Cloning Plus, 
Clonetech) 
 
Removal of FLAG epitopes for further transfection 
The 3xFLAG of pcDNA3.1vCDX2-3xFLAG and pcDNA3.1vCDX2(AUG)-3xFLAG is flanked by 
XhoI and XbaI restrictions sites. 1 µg DNA was digested overnight at 37 °C with 0.7U/µL XhoI and 
0.4U/µL XbaI in a 2x Tango buffer, all from Thermo-Scientific (Vilnius, Lithuania). The digested 
plasmids were separated by gel electrophoresis, and the large fragment was purified with E.Z.N.A. 
gel extraction kit spin- protocol from Omega biotek (Atlanta, Georgia, USA). The purified frag-
ments were incubated with dNTP’s (50mM in house solution, Roskilde, Denmark) klenow fragment 
and klenow buffer from Thermo-Scientific (Vilnius, Lithuania). The product was concentrated to 
~45ng/µL with vacuum distillation (speedvac concentrator, Spd1010, Thermo-electron corp.). The 
concentrated product was self-circulized with 0.5U/µL T4 ligase in a 1x T4 ligase buffer and 5% 
PEG4000 from Thermo-Scientific (Vilnius, Lithuania). The new circularized plasmid was amplified 
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in a Mach1
TM
 competent E. coli cells. Ampicillin resistance was used to screen for transfection, 
pUC19 as a positive transfection control. Plasmids were extracted with Nucleo Bond ® Xtra 
Midi/Maxi kit from Macherey-Nagel (Düren, Germany). Controls of the 3xFLAG removed from 
the plasmids were analyzed by digestion with XbaI, XhoI and PstI digestions. 
 
Transfection procedure for expression control of vCDX2 in human cells 
The transfection was performed twice, first using HEK293 and SW480 cell lines and later using 
SW480 and Caco-2 cell lines. The cells were transfected with a total of 1.2µg pr. well of 
pcDNA3.1vCDX2-3xFLAG, pcDNA3.1vCDX2(AUG)-3xFLAG, pCMV-GATA5-FLAG and 
pHIVdtomato, see table 3. pCMV-GATA5-FLAG was transfected as an internal standard and posi-
tive control for transfection. pHIVdtomato was transfected as a negative control. 
 
Table 3 Transfection combinations (TC) for western blot 
TC DNA in 
µg 
G5-FLAG pcDNA3.1 
vCDX2(AUG) 
pcDNA3.1 
vCDX2(CUG 
pHiv dTomato 
1 1.2    
2 0.6 0.6   
3 0.6  0.6  
4  1.2   
5   1.2  
6    1.2 
7 – suramin treated 0.6  0.6  
 
The transfection was performed by preparing the plasmid combinations to a total of 1.2 µg DNA pr 
transfection. The DNA was suspended in 150mM NaCl and PEI25 (2µM In house solution, Roskil-
de, Denmark) was added to a final concentration of 1µM. The DNA/PEI25 mixes was kept at room 
temperature for at least 1 hour prior to transfection. 
The DNA/PEI25 mix was transferred onto 7.0*10
5
 cells in a 6 well plate, containing 3 mL of 
growth media. The cells were spun and incubated for 48 hours at least, see appendix II for details. 
Three hours before lysing, Transfection combination (TC) seven, was treated with suramin to a 
concentration of 3µM and then the cells were washed and lysed according to transfection appendix. 
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The total protein concentration of the lysate was measured with Bradford reagent in order to stand-
ardize the protein concentration for the following western blot.  
10µg protein of the first transfection and 30µg protein of the second transfection, respectively were 
loaded in NuPAGE® Novex 4–12% Bis-Tris Midi Gel from Life Technologies (Carlsbad, Califor-
nia, USA) and the proteins separate by approximate size by electrophoresis. The gel was blotted 
onto a membrane, Invitrolon™ PVDF/Filter Paper Sandwich from Life Technologies (Carlsbad, 
California, USA) after separation, the details can be read in the appendix II. The vCDX2 and Gata5 
protein was detected through the FLAG epitope, in a two-step analysis with a primary and a sec-
ondary antibody. The primary anti-FLAG antibody, Monoclolonal ANTI-FLAG®M2 antibody 
from Sigma-Aldrich (St. Louis, Missuri, USA), was first bound to the FLAG epitope during incuba-
tion and gentle agitation. The membrane was washed and suspended with a secondary antibody, 
Goat Anti-Mouse IgG Horseradish Peroxidase #32430 from Thermo Scientific (Rockford, Illinois, 
USA), conjugated with for one hour. The gel was washed and added a luminescent substrate, Pierc-
es Dura Substrate #34075 from Thermo-Scientific (Vilnius, Lithuania). The band was visualized 
and size determined by comparison to SeeBlue® Plus2 Pre-Stained Standard marker from Life 
Technologies (Carlsbad, California, USA). 
 
Transfection procedure for vCDX2 regulation on MEP1A expression in human cells 
The transfection was performed using SW480 and Caco-2 cell lines. The cells were transfected with 
pcDNA 3.1, an empty vector, pcDNA3.1 vCDX2(AUG), pcDNA3.1 vCDX2 and two vectors pro-
vided by Dahlgaard K. pcDNA3.1 CDX2, an expression vector containing wild type CDX2 and 
pRC-CMVCDX2Δ55-136, an expression vector containing CDX2 with a deleted activation domain 
between amino acid 55 and 136(41), All CDX2 and CDX2 variants are expressed through a consti-
tutively cytomegalovirus (CMV) promoter. Reporter vectors used was pGL4.10-MEP1A containing 
a MEP1A-promoter coupled to luciferase gene Luc and pGL4.35 a vector with a Luc gene but with-
out a promoter. Finally the pHIV-dTomato was used as negative control as it contained no Luc or 
LacZ genes. All cells, except the negative control, were transfected with a vector with CMV pro-
moter coupled to LacZ, used as internal standard. The combinations transfected are depicted in table 
4. 
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Table 4 Transfection combinations expressed as ng for duallight assay 
    
Expression vectors 
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1 PGL4.10 (4.35) 50 25 37.5         187.5 
2 Pgl4.10-MEP1A 50 25 37.5         187.5 
3 Pgl4.10-MEP1A 50 25 25 12.5       187.5 
4 Pgl4.10-MEP1A 50 25 12.5   25     187.5 
5 Pgl4.10-MEP1A 50 25 12.5     25   187.5 
6 Pgl4.10-MEP1A 50 25 12.5       25 187.5 
7 Pgl4.10-MEP1A 50 25   12.5 25     187.5 
8 Pgl4.10-MEP1A 50 25   12.5   25   187.5 
9 Pgl4.10-MEP1A 50 25   12.5     25 187.5 
 
10 pHiv- dTomato 300               
 
The variants of CDX2 were transfected at twice the amount of CDX2, this led to difference in ex-
pression vector concentration which was adjusted with the addition of pcDNA 3.1. pUC19 was add-
ed up to a total of 300ng DNA pr. well. PEI25 (2µM in house solution, Roskilde, Denmark) was 
added to a concentration of 1µM. The DNA/PEI25 mixes was kept at room temperature for at least 
1 hour prior to transfection. The DNA/PEI25 mix was transferred onto 0.5*10
5
 cells pr. Well on 24-
well plates containing 1 ml of DMEM from Life Technologies (Carlsbad, California, USA) pr. well. 
Each transfection was done in quadruplicates. The wells were spun to bring the DNA/PEI25 into 
contact with the cells. The well plates were incubated for 48hours. The cells were washed and lysed 
according to appendix. The luciferase activity was measured on cell lysate, using reporter gene as-
say AB Dual-light
TM
 system from Applied Biosystems(Bedford, Massachusetts, USA) using 
Berthold Lumat LB 9501 Tube Luminometer from (Bad Wildbad, Germany).  
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Results 
Enhancing the translation of vCDX2 by replacement of the start codon 
The purpose of the cloning procedure is to enhance the translation of vCDX2 and determine if the 
CUG codon results in a protein product. The mutation was introduced by site directed mutagenesis, 
which changed the translation initiation site in pcDNA3.1vCDX2-3xFLAG from 5´-TTTCTGC-3´ 
to 5´-ACCATGG-3´. The mutation creates an AUG start codon in a strong Kozak sequence with a 
NcoI restriction site. The AUG start codon and the Kozak sequence will enhance translation of 
vCDX2. The NcoI site was added to provide a possible way to visualize the success of the proce-
dure as it will produce an extra fragment, when the plasmid is digested with NcoI restriction en-
zyme. According to the plasmid map, seen in figure 5, digestion of pcDNA3.1vCDX2-3xFLAG 
with NcoI restriction enzyme should yield 3 DNA-fragments with lengths of 3342 bp, 1884 bp and 
735 bp. The pcDNA3.1vCDX2(AUG)-3xFLAG should yield 4 DNA-fragments with lengths of 361 
bp, 1523 bp, 735 bp and 3342 bp.  
 
  
Figure 5 Plasmid maps:  
To the left is the original template with vCDX2(CUG) and to the right is mutated template with vCDX2(AUG) and the 
new NcoI site. Also shown in both vectors are the XhoI and XbaI sites that were used to remove the 3xFLAG-tag and 
the PstI site used a positive control in the FLAG removal restriction reactions.  
 
The result from the cloning of the changed pcDNA3.1vCDX2-3xFLAG was named 
pcDNA3.1vCDX2(AUG)-3xFLAG. Both vectors were digested with NcoI and visualized by gel 
electrophoresis; the results are seen in figure 6. The successful introduction of the mutation se-
quence was confirmed by the visualization of the four fragment of 3000-4000bp, 1500-2000bp, 
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700-1000bp and 300-400bp length for the pcDNA3.1vCDX2(AUG)-3xFLAG vector. Tree frag-
ments of 3000-4000bp, 1500-2000bp, 700-1000bp lengths for pcDNA3.1vCDX2-3xFLAG. 
 
 
Figure 6 plasmids digested 
with NcoI: Ethidium bromide 
stained agarose gel of the amplified 
pcDNA3.1vCDX2(AUG)-
3xFLAG. Lane 2 to 11. Lane 12 
contains the template pcDNA3.1-
vCDX2(CUG)-3xFLAG. Lane 1 
and 13 contains the ladder 
(O’Generuler 1kbp+, Thermo Sci-
entific),The top of gel shows the 
uncut plasmids and below is seen 
the NocI digested pcDNA3.1-
vCDX2-AUG-3xFLAG, four 
bands in lane 2-11, are clearly 
visible. Lane 12 contains the three 
bands of the template 
pcDNA3.1vCDX2(CUG)-
3xFLAG. 
 
 
Removal of FLAG epitopes for further transfection 
The 3xFLAG might interfere with the CDX2 and vCDX2 regulation of MEP1A expression. The 
3xFLAG will therefore be remove from the plasmid pcDNA3.1vCDX2-3xFLAG and 
pcDNA3.1vCDX2(AUG)-3xFLAG for later transfection of Caco-2 and SW480 cells. A double di-
gestion was performed with XhoI and XbaI from Thermo-Scientific (Vilnius, Lithuania). XhoI and 
XbaI restrictions enzymes will digest the 3x-FLAG sequence at both ends, and will excise the 3x-
FLAG from the plasmid, see figure 7. The small 75bp 3x-FLAG sequence was separated by 1% 
agarose gel electrophoresis from the digested plasmid. XbaI and XhoI function was controlled by 
digesting the plasmids once with each of the enzymes, see figure 8. The Plasmids contained 5´-3´ 
sticky ends after digestion. We then used the Klenow fragment that contain 5´-3´polymeraseI activi-
ty to create blunts ends prior to ligation, see appendix for protocol. Finally, the DNA was self-
circulized by ligase T4 activity, joining the 3´hydroxylgroup to the next 5´phosphate, see appendix 
for protocol. The newly circular plasmid was then named pcDNA3.1vCDX2(CUG) and pcDNA3.1-
vCDX2(AUG) and added a stop codon three amino acids after the vCDX2 gene sequence by the 
self-circulization seen in figure 7. Controls of the 3xFLAG removal, can be seen in figure 9.  
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Figure 7 The recognition site for XhoI and XbaI:  
The recognition sequence of XhoI is 5´-CTCGAG-3´, whereas the recognition sequence for XbaI is 5´-TCTAGA-3´. 
The total size of the 3x-FLAG is 75 bp. The top sequence shows the restriction site flanking the 3xFLAG-tag. Below is 
shown the sequence after 3xFLAG excision. The 5´-TAG-3´ colored grey is the in frame stop codon, the blue is the 
excised fragment of 3xFLAG. 
 
Figure 8 3xFLAG excision: 
Ethidium bromide stained agarose 
gel. Lane one and ten contain the 
ladder (O’Generuler 1kbp+, Thermo 
Scientific), second and sixth lane 
contains uncut template. Lane four 
and eight are single restriction site, 
XhoI. Five and nine is single re-
striction site, XbaI. Three and seven 
contain the double restriction site, 
XhoI and XbaI, A second band can 
be seen at about 75bp, indicating a 
successful removal of the 3xFLAG. 
The template in Lane two to five is 
pcDNA3.1vCDX2-3xFLAG, and 
lane six to nine is 
pcDNA3.1vCDX2(AUG)-3xFLAG 
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Transfection procedure for expression control of vCDX2 in human cells 
The purpose of the transfection was to determine the possibility of vCDX2(CUG) yielding a protein 
from the CUG start codon in the 5’ end. We also wanted to determine the size and quantity of the 
protein. vCDX2(AUG) protein was used to compare the relative translation of vCDX2(CUG). 
Both vCDX2 proteins expressed from pcDNA3.1vCDX2-3xFLAG and pcDNA3.1vCDX2(AUG)-
3xFLAG was tagged with a triplet of a high affinity FLAG epitopes, as no antibody for the N-
terminal of vCDX2 is available. The FLAG-tag makes it possible to visualize a successful transla-
tion of the gene with cell lysate from transfected cells in a western blot. 
The HEK293, SW480 and Caco-2 cells expressed vCDX2 from pcDNA3.1vCDX2(AUG)-3xFLAG 
in all transfections see figure 10-13. The vCDX2 from pcDNA3.1vCDX2-3xFLAG was expressed 
at detectable levels in TC five from HEK293, see figure 10, and first transfection of SW480, see 
figure 11, as well as the suramin treated culture, TC seven, of Caco-2 cells, see figure 13. The 
vCDX2 protein was found between 14-28 kDa markers, the calculated size was 20.8 kDa. Gata5-
FLAG was expressed in detectable quantities in TC one in HEK293, see figure 10. In the first trans-
fection of SW480 cells the Gata5-FLAG was expressed in detectable quantities in TC one and sev-
en, see figure 11. In TC five of the second transfection of SW480 cells a faint trace of a protein of 
 
Figure 9: Controls of the 
3xFLAG removal: 
Lane 1 and 10 contain the ladder 
(O’Generuler 1kbp+, Thermo Scien-
tific), lane 2 and 6 contains undigest-
ed of pcDNA3.1(CUG) and 
pcDNA3.1(AUG) respectively. Lane 
3 and 7 contains XbaI and XhoI di-
gested pcDNA3.1(CUG) and 
pcDNA3.1(AUG) respectively. Lane 
4 and 8 contains XbaI and PstI di-
gested pcDNA3.1(CUG) and 
pcDNA3.1(AUG) respectively. Lane 
5 and 9 contains XhoI and PstI di-
gested pcDNA3.1(CUG) and 
pcDNA3.1(AUG) respectively. 
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6-14 kDa in size was detected, see figure 12. Note that the bands in the western blots have artificial-
ly enhanced and cannot be compared to each other in relation to band intensity.  
 
 
Figure 10 Western blot from 
HEK293cells: 
A western blot depicting the expression of 
vCDX2 initiated from an AUG or CUG 
codon in HEK293 cells. The numbering 
corespond to the TC from table 3. M 
corespond to the SeeBlue Plus2 marker. TC 
1, 2, 4 and 5 shows bands between 14 and 
28 kDa markers. TC 1 also depicts a band at 
the 39 kDa mark.  
 
Figure 11 Western blot from the 
first transfection of SW480 cells: 
A western blot depicting the expression of 
vCDX2 initiated from an AUG or CUG 
codon in SW480 cells. The numbering 
corespond to the TC from table 3. M 
corespond to the SeeBlue Plus2 marker The 
TCs 2, 4 and 5 shows bands between 14 and 
28 kDa markers. TC 1 and 7 depicts a band 
at the 39 kDa mark.  
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Figure 12 Western blot from the 
second transfection of SW480 
cells: 
A western blot depicting the expression of 
vCDX2 initiated from an AUG or CUG 
codon in SW480 cells. The numbering 
corespond to the TC from table 3. M 
corespond to the SeeBlue Plus2 marker. 
The TCs 2 and 4 shows 2 bands between 
14 and 28 kDa markers. The TC 5 contains 
a very faint band between 6 and 14 kDa 
markers, the band has been artificialy 
enhanced and marked with a circle. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Western blot from Ca-
co-2 cells: 
A western blot depicting the expression of 
vCDX2 initiated from an AUG or CUG 
codon in Caco-2 cells. The numbering 
corespond to the TC from table 3. M 
corespond to the SeeBlue Plus2 marker. 
The TCs 2, 4 and 7 shows bands between 
14 and 28 kDa markers. 
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Regulation of MEP1A promoter by CDX2 and variants 
In order to quantify the effect of vCDX2 and CDX2 on regulation of MEP1A-promoter, we used the 
reporter gene assay AB Dual-light
TM
 system from Applied Biosystems(Bedford, Massachusetts, 
USA) using Berthold Lumat LB 9501 Tube Luminometer from (Bad Wildbad, Germany). MEP1A-
promotor activity coupled to luciferase in the pGL4.10-MEP1A was calculated against background 
measurement of pLG4.10 plasmid, and resulted in an increase in the luciferase gene expression for 
all samples, see figure 14 and 15. Fold induction was calculated against the basic readings from the 
empty vector pGL4.10. The same results are seen as a fold induction calculated against pGL4.10-
MEP1A, see figure 16 and 17.  
For Caco-2 cells the difference in fold increase between constructs containing only the CDX2 ex-
pression vector and constructs containing the CDX2 as well as a vCDX2 expression vector, is sig-
nificant,        . Data are expressed as mean values   (   ), See figure 16. 
For SW480 cells the difference in fold increase between constructs containing only the CDX2 ex-
pression vector and constructs containing the CDX2 as well as the vCDX2(AUG) expression vec-
tor, is significant,        . Data are expressed as mean values   (         ). However, the 
difference in fold increase between constructs containing only the CDX2 expression vector and 
constructs containing the CDX2 as well as the vCDX2(CUG) or CDX2Δ55-136 expression vectors, 
show no significance ,        . Data are expressed as mean values   (         ), see fig-
ure 17 
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Figure 14 Luciferase activity in lysed Caco-2 
cells: Caco-2 cells transfected with the reporter/promoter 
construct pGL4.10(4.35) and pGL4.10-MEP1A. Lucifer-
ase activity is normalized against β-galactosidase activity. 
Expression and reporter vectors used are shown under the 
graph. Data are expressed as mean values   (   ). 
Figure 15 Luciferase activity in lysed SW480 
cells: SW480 cells transfected with the reporter construct 
pGL4.10(4.35) and pGL4.10-MEP1A. Luciferase activity 
is normalized against β-galactosidase activity. Expression 
and reporter vectors used are shown under the graph. Data 
are expressed as mean values   (   ). 
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Figure 16 Luciferase activity in lysed Caco-2 
cells: Caco-2 cells transfected with the reporter/promoter 
construct pGL4.10(4.35) and pGL4.10-MEP1A. Lucifer-
ase activity is normalized against β-galactosidase activity. 
Expression and reporter vectors used are shown under the 
graph. Data are expressed as mean values   (   ). 
Figure 17 Luciferase activity in lysed SW480 
cells: SW480 cells transfected with the reporter construct 
pGL4.10(4.35) and pGL4.10-MEP1A. Luciferase activity is 
normalized against β-galactosidase activity. Expression and 
reporter vectors used are shown under the graph. Data are 
expressed as mean values   (   ). 
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Discussion  
The existence of vCDX2 has so far only been confirmed on the mRNA level and the presence of the 
protein is yet to be determined in vivo. The vCDX2 mRNA lacks an AUG start codon, it is therefore 
plausible that vCDX2(CUG) is expressed from a non-AUG codon or not at all. The 5’ end of the 
mRNA contains a CUG codon infram with exon-2 and exon-3 of CDX2, the most common alterna-
tive start codon. We transfected in vitro cultures of the colonic adenocarcinoma cells Caco-2 and 
SW480, as well as HEK293 cells with a vectors containing a 3xFLAG tagged version of the 
vCDX2, and a modified vCDX2 with the initiation changed from a CUG codon, in a weak Kozak 
sequence, to an AUG codon in a strong Kozak sequence. The transfected cells were then analyzed 
for the presence of vCDX2 via a western blot, see figure 10-13. We expect the translation of the 
Flag-tagged protein from vCDX2 to be at 20.8kDa. The result from the western blot shows that 
vCDX2(CUG) and vCDX2(AUG) translation occurs in all three analyzed cultures, confirming that 
the vCDX2 is translated into a protein. The translation efficiency is however very dependent on the 
initiating codon. For all cases the visible bands were found to be of equal size, ~20kDa, except for 
the second SW480 transfection where a faint, unexpected band, of 6-14 kDa, was seen. However 
we suspect this to be an artifact as the intensity was only slightly higher than the background. The 
presence of Gata5-FLAG was meant to be used as internal standard, but the poor translation, lead us 
to discard it. 
 The vCDX2(AUG) is certainly initiated from the inserted AUG codon, probably because of the 
strong Kozak sequence. That the western blot bands from vCDX2(AUG) and vCDX2(CUG) pro-
teins are of the same size, strongly indicate, that the vCDX2(CUG) is initiated from the proposed 
CUG codon.  
 
The vCDX2(AUG) was found to be translated in all three cultures, whereas vCDX2(CUG) was 
only successfully detected in HEK293 and SW480 cultures which had not been treated with su-
ramin, see below, with the highest plasmid transfection. This indicates that vCDX2(CUG) is ineffi-
ciently translated under normal conditions in vitro. In IBD patients, the cells are exposed to a high 
degree of cellular stress, which is known to increase CUG codon translation, see section vCDX2 
possible influence on IBD. In order to emulate cellular stress and increase translation from CUG 
start codon, cells were treated with suramin. Experiments performed by Starck R.S. et al. (33) 
showed that suramin enhanced the expression from CUG start codons, while down regulating ex-
pression from AUG start codons. Our results are comparable to the Starck R.S et al. (33) experi-
ment, in that our suramin treated Caco-2 cells produced a visible band on the western blot corre-
sponding to vCDX2(CUG) only when treated with suramin, see TC seven figure 13. The suramin 
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treatment however, did not improve the expression of vCDX2(CUG) in HEK293 and SW480 trans-
fection combinations at least not to a degree where it could be visualized in a western blot. Even 
though the cells could produce a weak band when transfected with the highest concentration of 
pcDNA3.1vCDX2(CUG). Starck R.S. et al. (33) suggested that the improvement of CUG initiation 
was due to an eIF2 independent pathway, up-regulated during cellular stress. The eIF2 independent 
pathway is proposed to initiate transcription of CUG with leucine-tRNA instead of methionine-
tRNA. The eIF2 independent pathway might be more induced in the Caco-2 cells, and the expres-
sion of vCDX2(CUG) in SW480 and HEK293 might be from the wobble effect and not from the 
eIF2 independent pathway, explaining the results. An analysis for methionine or leucine of the N-
terminal for of the vCDX2(CUG) proteins could have confirmed if this was a feasible explanation. 
There is however some key differences in the experiments. In our experiment we used a concentra-
tion of 3.3mM suramin, approximately 100 times the concentration used in the Starck R.S. et al. 
(33) experiments, which unlike ours, was performed on cell lysate. In order to discern the full effect 
of suramin on vCDX2(CUG) expression more experiments would be needed.  
One key question in this experiment was whether the vCDX2(CUG) mRNA was translated into a 
protein, this we proved, but only in vitro. However the Caco-2 is a highly differentiated colonic 
adenocarcinoma (30;42;43) and therefore is one of the best in vitro models for normal IEC in this 
regard, suggesting that the in vitro result obtained for Caco-2, are transferable to in vivo. The Caco-
2 result also indicated that cellular stress induced by suramin, plays an important role for the ex-
pression of vCDX2(CUG). The effect of suramin may be comparable to the UPR induction by 
TNF-α, but a more direct assay would be needed to confirm this. 
The hypothesis was that vCDX2 competed with CDX2 to bind on the MEP1A-promoter, due to the 
exon-1 encoded protein activation domain, that vCDX2 is lacking. To determine the interaction 
between vCDX2 and CDX2 on the MEP1A-promoter we performed a dual luminescence reporter 
gene assay. The reporter gene assay was used to quantify the fold induction of MEP1A-promoter 
vector, when regulated by CDX2 and variants thereof. All results were normalized with β-
galactosidase activity as internal standard, in order to counter differences in transfection efficacy. 
Results are shown as fold induction of the MEP1A-promotor activity from SW480 and Caco-2 cells 
containing no CDX2 or vCDX2 expression vector as the baseline, see figure 16 and 17.  
The Caco-2 MEP1A-promotor baseline was much higher than SW480 leading to a lower fold induc-
tion by CDX2 see figure 14 and 15. This corresponds well with Caco-2 having a higher intrinsic 
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CDX2 expression, causing a higher MEP1A-promotor activity in our baseline do to the fact that 
CDX2 expression in IEC determents the differentiation state (30;43). The Caco-2 cells that were 
transfected with the MEP1A-promotor and CDX2 expression had a significantly higher MEP1A-
promotor activity when compared to MEP1A baseline. The CDX2 induced a 2.8 fold increase, sig-
nificantly higher than any other vector combination, see figure 16. In SW480 the CDX2 induced a 
6.7 fold increase see figure 17. The hypothesis is that the two variants of CDX2 proteins, 
vCDX2(AUG) and vCDX2(CUG), have no caudal like protein activation domain, therefore lacking 
the ability to enhance MEP1A-promotor expression to the same degree as CDX2. We used another 
expression vector containing CDX2Δ55-136, which is CDX2 with a deleted activation domain be-
tween amino acid 55 and 136(39), in order to compare the inhibitory nature to that of vCDX2. This 
is confirmed by the activity of the MEP1A-promotor in Caco-2 and SW480 cells, being significant-
ly higher in all cases where the CDX2 vector’s effect is compared to the effects of the three variant 
CDX2 proteins. The fold induction of the MEP1A-promotor activity were 1.3, 1.0 and 1.6 for 
SW480 transfected with vCDX2(AUG), vCDX2(CUG) and CDX2Δ55-136 respectively and 0.8, 1.0 
and 0.7 for Caco-2 cells transfected with vCDX2(AUG), vCDX2(CUG) and CDX2Δ55-136 respec-
tively.  
The dominant negative interactions between the CDX2 and the three variants of CDX2 on the 
MEP1A-promoter, was determined by co-transfection of SW480 and Caco-2 cells. The SW480 cells 
showed significant higher MEP1A-promoter activity when only transfected with the CDX2 vector, 
when compared to the vector combination of CDX2 + vCDX2(AUG) with a 6.7 and 4.7 fold induc-
tion respectively. The SW480 cell transfected with an expression vector combination of CDX2, 
CDX2 + vCDX2(CUG) and CDX2 + CDX2Δ55-136 surprisingly resulted in no significant differ-
ence in MEP1A-promoter activity see Figure 17 with 6.7, 7.3 and 5.6 fold induction respectively. 
However one of the samples of the SW480 with the CDX2 vector failed, leaving us with a sample 
size of three, weakening the statistical analysis and creating an unfavorable large standard error. 
The large standard error potentially masks differences between MEP1A-promoter activities of cells 
transfected with CDX2 when compared to SW480 cells transfected with any other vector combina-
tions.  
The Caco-2 cells showed, as already mentioned significant higher MEP1A-promoter activity of the 
cells only transfected with the CDX2 vector than any other vector combination. The fold induction 
was 2.2, 2.4 and 1.9 for co-transfection of CDX2 with vCDX2(AUG), vCDX2(CUG) and CDX2Δ55-
136 respectively, compared to 2.8 fold induction for CDX2 alone. Indicating that co-transfection 
with any one of the three variants of CDX2 reduce the CDX2 induced MEP1A-promoter activity. 
The low translation efficiency of the vCDX2(CUG) as seen in the western blot (figur) is a factor 
that needs to be addressed. Both Caco-2 and SW480 cells showed no significant difference between 
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baseline and vCDX2(CUG) transfected cells with no fold induction or reduction. The co-
transfection result are however ambiguous, with a significant decrease in the Caco-2 cells and an 
insignificant increase in the SW480 cells. 
In conclusion we showed that all three variants of CDX2 reduced the activity of CDX2 when co-
transfected in Caco-2 cells, indicating that the variants interfere with CDX2 transcriptional regula-
tion of the MEP1A-promoter negatively. The result of SW480 are less conclusive, owing to an infe-
rior sample size, although the MEP1A-promotor activity was significantly lower when cells were 
co-transfected with CDX2 and vCDX2(AUG), compared to CDX2. The same results couldn’t be 
reproduced with vCDX2(CUG) in SW480. The similarity in inhibition of vCDX2 and CDX2Δ55-
136 co-transfected with CDX2 indicates that the dominant negative effect of vCDX2 stems from the 
lack of the exon-1 encoded activation domain, and not from a functional gain of the alternative ex-
on-1. 
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Conclusion 
In our research we showed that the vCDX2(CUG) transcripts does produce a protein product in 
HEK293, SW480 and Caco-2 cell cultures. The translation was however very inefficient as the 
HEK293and SW480 cell only produced protein at detectable levels with the highest amount of 
transfected vectors. The Caco-2 cells in contrast only expressed vCDX2(CUG) when treated with 
suramin, unlike the HEK293and SW480 cells. The lack of translation is very likely caused by the 
inefficient initiation of a CUG codon located near the 5’ cap of the mRNA. The conversion of said 
CUG codon to an AUG codon in a strong Kozak sequence profoundly enhanced the translation and 
detectable levels were measured in all transfected cultures. The vCDX2 proteins was further ana-
lyzed and found to compete with CDX2 for binding of the MEP1A-promotor when co-transfected. 
The transfection in SW480 cells showed significant competition for the CDX2 binding on the 
MEP1A-promotor for the vCDX2(AUG), but vCDX2(CUG) showed no significant reduction in the 
effect of CDX2 on the MEP1A-promotor. The lack of effect from vCDX2(CUG) is due to a poor 
expression from the CUG start codon. However the low sample size doesn’t allow further conclu-
sions on the matter. In Caco-2 cells both vCDX2 proteins decreased the CDX2 dependent MEP1A-
promotor activity significantly. The vCDX2(CUG) interference on CDX2 MEP1A regulation can 
therefore be classified as dominant negative in nature. 
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Perspective 
Our study has not only elucidated that an isoform of CDX2 does exist but found that it behaves as a 
dominant negative form of the CDX2 regulatory function on the MEP1A-promotor in human cell. 
We know that CDX2 is required for a transcription of several others intestinal specific genes in rela-
tion to cell differentiation, see figure 2. It could therefore be of interest to investigate vCDX2 effect 
on cell proliferation, differentiation and cellular expression of intestine specific genes when CDX2 
is down-regulated in vitro.  
A hypothesis has suggested that vCDX2 maintain the epithelium in an inflamed and undifferentiat-
ed state seen in IBD patients. IBD is a disease with socioeconomics consequences for both the pa-
tients and the society. The treatment is often based on biological pharmaceuticals, such as antibod-
ies against key mediators of the pathogenesis, and surgical interventions. The role of vCDX2 in the 
pathogenesis of IBD could also investigated by further research projects on functional studies on 
cell cultures to determine the exact mechanism behind the occurrence of vCDX2, its translation of 
its CUG start codon and if vCDX2 is a cause or effect of IBD. 
CDX2 antibodies are used in the daily clinical setting where it serves as an intestinal specific nucle-
ar staining to diagnose adenocarcinoma. In relation to verify the existence of vCDX2 protein in bi-
opsies from IBD patients it would be relevant to develop an antibody specifically for vCDX2. Such 
antibodies could potentially increase the diagnostic sensitivity of biopsies obtained by colonoscopy 
from patients with a low grade inflammatory state of IBD. Furthermore the development of phar-
maceuticals specially targeting the exon-1 vCDX2 mRNA might have a dramatic effect on the path-
ogenesis of IBD, if indeed vCDX2 is a part of the etiology.  
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Appendix I 
Overview of methods 
 
 
 
 
Figure x flowchart of the laboratory methods used. 
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Appendix II 
Methods protocol 
Site direted mutagenesis   
 
Components 20µL reaction Final concentraion 
H2O Variable  Variable 
5x Phusion GC Buffer from 
Clonetech laboratories inc. 
(Mountain view, California USA) 
0.4µL 1 
10mM dNTP´s 0.4µL 200µM of each nucleotide 
Reverse primer 1 µL 0.5µM 
Forward primer 1 µL 0.5µM 
Template DNA 4ng/µL 1µL  
DMSO 0.6 µL* 3% 
Phusion Hot start II DNA 
polymerase 2U/µL from Clonetech 
laboratories inc. (Mountain view, 
California USA) 
0.5µL 0.02U/µL 
Table for pipetting instructions for site-directed mutagenesis. * DMSO only used in three of the 
PCR solutions.  
 
PCR program: 
1 x 98C
o
 at 30 seconds 
7 x 98 C
o 
at 30 secondt, 60, 61, 62, 63 C
o
 *at 15 seconds and 72 C
o
 at 210 seconds 
30 x  98 C
o
 at 30 seconds, 72 C
o
 at 210 seconds, 72 C
o
 at 420 seconds  
4 C
o 
until removed from the heat block and visualised on a gel  
*Different annealing temperatures where used because we were to assert about optimal 
temperature for the PCR. DMSO was added in three duplicated samples with annealing 
temperatures at 60, 61 and 62 C
o
.  
Gel purification 
This procedure where done according to spin protocol from E.Z.N.A Gel Extraction kit from 
Omega Biotek (Atlanta, Georgia, USA) 
 
Ligation 
Components 10µL reaction 
Gel purification end product ≈ 3.5ng/µL** 7µL (≈24.5ng)  
Mili Q H2O 1µL 
5 x infusion HD enzyme from Clonetech 
laboratories inc. (Mountain view, California 
USA) 
2µL 
Table for pipetting instructions for ligation procedure for sticky ends. ** linearized plasmid in 
elution buffer solution.  
Mix the solutions and incubate for 15 min at 50C
o
.  stored on ice after the procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 
Transformation of Mach-1™ Competent Cells 
Blends 
50µL Mach-1 cells + 3µL (≈2.45ng/µL)  circular PCR product   
50µL Mach-1 cells + 5µL pUC19 (10ng/µL) (positive control) 
50µL Mach-1 cells + 5µL H2O (negative control)  
Table for pipetting instructions for transformation procedure of Mach-1™ cells.  
pUC19 was used as a positive control to determin if the transformation succeeded or not. The 
negative control with H2O is to test if Mach-1 cells could grow without a plasmid with 
ampicillin resistance. Mixtures where mixed as seen in table and then incubated on ice for 30 
minutes. There after heat chocked in water bath at 42C
o
 and thereafter incubated on ice for 5 
minutes. 200µL SOC-medium where added in the tubes and and the content where smeared on 
AMP-agar plates. Incubated until next day at 38 C
o
. Clones with PCR product where selected
 
and each clone grafted in tube and grown over night with 50 mL LB media, 50µL ampicillin 
stock solution(100mg/mL)  
 Purification of plasmids 
This procedure where done according to the spin protocol from Pure Link® Quick Plasmid 
Miniprep Kit from Life technologies (Carlsbad, California, USA)  
 
Digest  
Components Mix ratio 
H2O 1:4 
Tango buffer 10x (Thermo-Scientific, Vilnius, 
Lithuania) 
1x 
NcoI  1:20 
Mini prep DNA 2ng/µL 1:1.666 
Table for pipetting instructions for digest with NcoI.  
Ten samples were run with NcoI and mini prep DNA, another ten where run without NcoI, but 
still with mini prep DNA as a negative control. Two samples were also run with the original 
template DNA instead of mini prep DNA and then with and without NcoI where visualised to 
compare with our modified construct and to see that the DNA fragment sizes matched with 
expected sizes.  H2O, Tango buffer and NcoI where added was added into mini prep DNA 
solution. The mixed solution where then incubated at 37C
o
 overnight. The product where then 
visualised on a gel.  
 
 
 
 
 
 
 
Transfection of human cells   
DNA mix DNA in ug  
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1 PGL4.10  (4.35) 0.4 0.2 0.3 
    
1.5 2.4 
2 Pgl4.10-mep1a 0.4 0.2 0.3 
    
1.5 2.4 
3 Pgl4.10-mep1a 0.4 0.2 0.2 0.1 
   
1.5 2.4 
4 Pgl4.10-mep1a 0.4 0.2 0.1 
 
0.2 
  
1.5 2.4 
5 Pgl4.10-mep1a 0.4 0.2 0.1     0.2   1.5 2.4 
6 Pgl4.10-mep1a 0.4 0.2 0.1 
   
0.2 1.5 2.4 
7 Pgl4.10-mep1a 0.4 0.2 
 
0.1 0.2 
  
1.5 2.4 
8 Pgl4.10-mep1a 0.4 0.2 
 
0.1 
 
0.2 
 
1.5 2.4 
9 Pgl4.10-mep1a 0.4 0.2 
 
0.1 
  
0.2 1.5 2.4 
10 pHiv- dTomato 2.4               2.4 
Table of DNA amounts added into transfected cells for dual light assay, the amount of DNA is 
split between 8 transfections. 
Dilute 5µL the mini prep product with 495µL 150mM NaCl. Then for each DNA mix take 
equal amounts of DNA mix and 2µM PEI25 (in house solution Roskilde, Denmark) and add 
together and let incubate for one hour at room temperature. Then add the PEI25/DNA mix in the 
empty cell wells and add the human cells within fresh DMEM media on top off the solution. 
Cell concentrations were 50.000 cells/well for the cells used for dual light assay cells and 
700.000 cells/well for the cells used for western blot. Spin the plates afterwards at 1200 RPM 
for 5 minutes and then incubate at 37C
o
 0.5% CO2 for two days. 
DNA 
mix 
DNA 
in µg 
G5-FLAG pcDNA3.1 
vCDX2(AUG) 
pcDNA3.1 
vCDX2(CUG 
pHiv 
dTomato 
Total 
ammount 
1 2.4    2.4 
2 1.2 1.2   2.4 
3 1.2  1.2  2.4 
4  2.4   2.4 
5   2.4  2.4 
6    2.4 2.4 
7 1.2  1.2  2.4 
Table of DNA amounts added into the transfected cells for western blot, the amount is split 
between 2 transfection. 
 Western Blot  
The transfected cells where lysed and the cells from well 7 was three hours beforehand treated 
with 1,6mg suramin.  
The samples were then added to a gel into a Bolt
TM
 Mini Gel Tank (from Novex by life 
technologies, Carlsbad, California, USA) and were run with MES and MOPS buffer one for 
each run. Together with the lysed cells there was also added loading buffer.  
After the gel electrophorese the gel where blotted onto a membrane according to XCell II
TM
 
Blot Module, where 500ml transfer buffer (0.5X Tris-Glycine buffer, 20% ethanol) was used.  
Afterwards the membrane was stored at 4Co for two days and then incubated with blocking 
buffer for 30 minutes. Then the membrane was washed two times for 20 min with 20mL wash 
buffer and then stained with the primary antibody, Monoclonal ANTI-FLAG® M2 antibody 
produced in mouse and then added onto the membrane and incubated at 4C
o
 for one day.  Then 
the secondary antibody, Stabilized Goat Anti-Mouse IgG (H+L), Peroxidase Conjugated 
(Thermo Scientific, Rockford, USA) was diluted in dilution buffer and was added onto the 
membrane and incubated for one hour at room temperature. Following the membrane was 
washed for four times ten minutes with wash buffer and wrapped in a plastic pocket and 1.5ml 
of Super signal West Dura extended duration substrate from Thermo-Scientific (Vilnius, 
Lithuania) which were added in equal amounts and added evenly onto the membrane without 
exposure to light. Afterwards the membrane was incubated at room temperature for five minutes 
and the visualised.  
 
Flag removal with double digest 
Digest FLAG-sequences with XbaI and XhoI. (Restriction protocol) 
Components Amount of components. Total volume ≈20µL 
H2O 2µL 
10xTango buffer (Thermo-Scientific, Vilnius, 
Lithuania) 
4µL (2x) 
DNA 1µg 
XhoI 0.7U/µL 
XbaI 0.4U/µL 
Table for pipetting instructions for double digest for FLAG removal with XhoI and XbaI 
Controls were also done to validate the results. After the double digest sticky ends were 
changed to blunt ends with Klenow fragments. Afterwards they were ligated.  
Components 20µL solution 
DNA 15µL 
H2O 2µL 
Klenow Buffer 10x (Thermo-Scientific, 
Vilnius, Lithuania) 
2µL 
Klenow fragment 0.5µL 
dNTPs  0.5µL 
Table for pipetting instructions for insert of Klenow fragments.  
Ligation 
Components 10µL solution 
DNA 1µL 
T4 buffer 10x (Thermo-Scientific, Vilnius, Lithuania) 1µL 
Ligase T4 (Thermo-Scientific, Vilnius, Lithuania) 1µL 
H2O 6µL 
PEG 4000 (Thermo-Scientific, Vilnius, Lithuania)  1µL 
Table for pipetting instructions for ligation procedure for blunt ends.  
Concentrations where mixed together and incubated for one hour at 22C
o
 and for 65C
o
 for ten 
minutes. 
 
Maxi prep 
Maxi prep was done according to Nucleo Bond® Xtra Midi / Maxi kit (from Macherey-Nagel, 
Düren, Germany)  
 
 
  
Reporter Assay 
Reporter assay were done according to AB(applied Biosystems) Dual-Light
TM
 system, reporter 
gene assay protocol (from applied biosystems, Bedford, Massachusetts) and the luciferase 
where measured on a Lumat LB 9501 berthold tube luminometer.  
